AEON Biopharma postponed its planned initial public offering as the stock market volatility continues to impact the IPO landscape.
We'll update this page as new information becomes available.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.50 |
|---|---|
| 52-week range | $0.38 - $239.76 |
| 50-day moving average | $0.91 |
| 200-day moving average | $43.67 |
| Wall St. target price | $360.00 |
| PE ratio | 0.0001 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $5,250.96 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.5013 from 2025-05-02
| 1 week (2025-04-25) | 16.47% |
|---|---|
| 1 month (2025-04-04) | 7.58% |
| 3 months (2025-02-05) | 316.02% |
| 6 months (2024-11-05) | -42.83% |
| 1 year (2024-05-03) | -70.51% |
|---|---|
| 2 years (2023-05-04) | -99.93% |
| 3 years (2022-05-04) | 707.04 |
| 5 years (2020-05-01) | N/A |
Valuing AEON Biopharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AEON Biopharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AEON Biopharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, AEON Biopharma shares trade at around 0x recent earnings.
However, AEON Biopharma's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -348.25% |
| Return on equity TTM | 0% |
| Profit margin | 0% |
| Book value | $-51.43 |
| Market Capitalization | $5.3 million |
TTM: trailing 12 months
We're not expecting AEON Biopharma to pay a dividend over the next 12 months.
You may also wish to consider:
AEON Biopharma's shares were split on a 1:72 basis on 25 February 2025 . So if you had owned 72 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your AEON Biopharma shares – just the quantity. However, indirectly, the new 7100% higher share price could have impacted the market appetite for AEON Biopharma shares which in turn could have impacted AEON Biopharma's share price.
Over the last 12 months, AEON Biopharma's shares have ranged in value from as little as $0.375 up to $239.76. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while AEON Biopharma's is 0.35. This would suggest that AEON Biopharma's shares are less volatile than average (for this exchange).
To put AEON Biopharma's beta into context you can compare it against those of similar companies.
AEON Biopharma, Inc. , a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co. , LTD. , and Viatris Inc. The company is based in Irvine, California.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .